TY - JOUR
T1 - Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
AU - Hall, Matthew D.
AU - Anderson, James M.
AU - Anderson, Annaliesa
AU - Baker, David
AU - Bradner, Jay
AU - Brimacombe, Kyle R.
AU - Campbell, Elizabeth A.
AU - Corbett, Kizzmekia S.
AU - Carter, Kara
AU - Cherry, Sara
AU - Chiang, Lillian
AU - Cihlar, Tomas
AU - De Wit, Emmie
AU - Denison, Mark
AU - DIsney, Matthew
AU - Fletcher, Courtney V.
AU - Ford-Scheimer, Stephanie L.
AU - Götte, Matthias
AU - Grossman, Abigail C.
AU - Hayden, Frederick G.
AU - Hazuda, Daria J.
AU - Lanteri, Charlotte A.
AU - Marston, Hilary
AU - Mesecar, Andrew D.
AU - Moore, Stephanie
AU - Nwankwo, Jennifer O.
AU - O'Rear, Jules
AU - Painter, George
AU - Singh Saikatendu, Kumar
AU - Schiffer, Celia A.
AU - Sheahan, Timothy P.
AU - Shi, Pei Yong
AU - Smyth, Hugh D.
AU - Sofia, Michael J.
AU - Weetall, Marla
AU - Weller, Sandra K.
AU - Whitley, Richard
AU - Fauci, Anthony S.
AU - Austin, Christopher P.
AU - Collins, Francis S.
AU - Conley, Anthony J.
AU - Davis, Mindy I.
N1 - Publisher Copyright:
© 2021 Published by Oxford University Press for the Infectious Diseases Society of America 2021.
PY - 2021/7/15
Y1 - 2021/7/15
N2 - The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
AB - The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
KW - SARS-CoV-2
KW - antiviral therapeutics
KW - emerging modalities
KW - preclinical
KW - proteases
KW - viral replication machinery
UR - http://www.scopus.com/inward/record.url?scp=85112055622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112055622&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiab305
DO - 10.1093/infdis/jiab305
M3 - Article
C2 - 34111271
AN - SCOPUS:85112055622
SN - 0022-1899
VL - 224
SP - S1-S21
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -